![](https://library.celltelligence.com/wp-content/uploads/2023/04/Screenshot-2023-04-12-at-18.09.31.png)
$0
Adaptimmune and GSK Agree to Terms for PRAME and NY-ESO Programs Transfer; Kristin Yarema to Serve as Poseida’s President for Cell Therapy; Mythili Koneru Appointed as Legend’s CMO
On Tuesday, April 11, Adaptimmune announced (press release) the terms of the agreement with GSK for transferring back PRAME and NY-ESO programs. On the same day, Poseida and Legend reported the appointments of Kristin Yarema as Poseida’s Cell Therapy President (press release) and Mythili Koneru as Legend’s CMO (press release). Below, Celltelligence provides insights on the transition of GSK’s PRAME and NY-ESO programs back to Adaptimmune, while discussing the potential benefits of the new appointments for Poseida and Legend.